The development of rifabutin for prophylaxis against Mycobacterium avium complex infections

F. P. Siegal, Barbara Weiser, Harold Burger, K. Gehan, J. W M Gold, B. A. Wynne, S. D. Nightingale

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rifabutin (formerly ansamycin), a semisynthetic derivative of rifamycin-S, has been in clinical use since 1982, initially as part of clinical efforts to treat disseminated infections with Mycobacterium avium complex (MAC) in the acquired immune deficiency syndrome (AIDS). Because of preliminary data suggesting a possible role as an antiretroviral agent, dose-related toxicities of the drug were explored in the mid-1980s. At high doses in patients with AIDS-related complex, a polyarthralgia syndrome developed, accompanied in some parts by uveitis. While having no useful activity in vivo against HIV-1, rifabutin appeared to prevent or delay the onset of clinically disseminated MAC infections in AIDS patients. These preliminary studies led to two identical prospective, placebo-controlled trials of rifabutin for the prevention of disseminated MAC infection, in which the principal endpoint was the reduction of MAC bacteraemia. Over 1100 subjects who had prior AIDS-defining opportunistic infections and ≤ 200 CD4 cells·mm-3 were randomized. Rifabutin use was associated with significant reduction in the frequency of MAC bacteraemia (60%), with concomitant reductions in symptoms related to MAC. Drug-related toxicity was minimal. These studies established the principal of MAC prophylaxis, as well as the safety and efficacy of rifabutin for the prevention of MAC infections in AIDS.

Original languageEnglish (US)
Pages (from-to)98-101
Number of pages4
JournalEuropean Respiratory Review
Volume5
Issue number25
StatePublished - 1995
Externally publishedYes

Fingerprint

Rifabutin
Mycobacterium avium Complex
Infection
Acquired Immunodeficiency Syndrome
Bacteremia
Drug-Related Side Effects and Adverse Reactions
Anti-Retroviral Agents
Uveitis
Opportunistic Infections
Arthralgia
HIV-1
Placebos
Safety

Keywords

  • Acquired immunodeficiency syndrome
  • Human immunodeficiency virus
  • Mycobacterial prophylaxis
  • Mycobacterium avium
  • Rifabutin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Siegal, F. P., Weiser, B., Burger, H., Gehan, K., Gold, J. W. M., Wynne, B. A., & Nightingale, S. D. (1995). The development of rifabutin for prophylaxis against Mycobacterium avium complex infections. European Respiratory Review, 5(25), 98-101.

The development of rifabutin for prophylaxis against Mycobacterium avium complex infections. / Siegal, F. P.; Weiser, Barbara; Burger, Harold; Gehan, K.; Gold, J. W M; Wynne, B. A.; Nightingale, S. D.

In: European Respiratory Review, Vol. 5, No. 25, 1995, p. 98-101.

Research output: Contribution to journalArticle

Siegal, FP, Weiser, B, Burger, H, Gehan, K, Gold, JWM, Wynne, BA & Nightingale, SD 1995, 'The development of rifabutin for prophylaxis against Mycobacterium avium complex infections', European Respiratory Review, vol. 5, no. 25, pp. 98-101.
Siegal, F. P. ; Weiser, Barbara ; Burger, Harold ; Gehan, K. ; Gold, J. W M ; Wynne, B. A. ; Nightingale, S. D. / The development of rifabutin for prophylaxis against Mycobacterium avium complex infections. In: European Respiratory Review. 1995 ; Vol. 5, No. 25. pp. 98-101.
@article{1d590b2e4f5547efba7ec01cc6879c1d,
title = "The development of rifabutin for prophylaxis against Mycobacterium avium complex infections",
abstract = "Rifabutin (formerly ansamycin), a semisynthetic derivative of rifamycin-S, has been in clinical use since 1982, initially as part of clinical efforts to treat disseminated infections with Mycobacterium avium complex (MAC) in the acquired immune deficiency syndrome (AIDS). Because of preliminary data suggesting a possible role as an antiretroviral agent, dose-related toxicities of the drug were explored in the mid-1980s. At high doses in patients with AIDS-related complex, a polyarthralgia syndrome developed, accompanied in some parts by uveitis. While having no useful activity in vivo against HIV-1, rifabutin appeared to prevent or delay the onset of clinically disseminated MAC infections in AIDS patients. These preliminary studies led to two identical prospective, placebo-controlled trials of rifabutin for the prevention of disseminated MAC infection, in which the principal endpoint was the reduction of MAC bacteraemia. Over 1100 subjects who had prior AIDS-defining opportunistic infections and ≤ 200 CD4 cells·mm-3 were randomized. Rifabutin use was associated with significant reduction in the frequency of MAC bacteraemia (60{\%}), with concomitant reductions in symptoms related to MAC. Drug-related toxicity was minimal. These studies established the principal of MAC prophylaxis, as well as the safety and efficacy of rifabutin for the prevention of MAC infections in AIDS.",
keywords = "Acquired immunodeficiency syndrome, Human immunodeficiency virus, Mycobacterial prophylaxis, Mycobacterium avium, Rifabutin",
author = "Siegal, {F. P.} and Barbara Weiser and Harold Burger and K. Gehan and Gold, {J. W M} and Wynne, {B. A.} and Nightingale, {S. D.}",
year = "1995",
language = "English (US)",
volume = "5",
pages = "98--101",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "25",

}

TY - JOUR

T1 - The development of rifabutin for prophylaxis against Mycobacterium avium complex infections

AU - Siegal, F. P.

AU - Weiser, Barbara

AU - Burger, Harold

AU - Gehan, K.

AU - Gold, J. W M

AU - Wynne, B. A.

AU - Nightingale, S. D.

PY - 1995

Y1 - 1995

N2 - Rifabutin (formerly ansamycin), a semisynthetic derivative of rifamycin-S, has been in clinical use since 1982, initially as part of clinical efforts to treat disseminated infections with Mycobacterium avium complex (MAC) in the acquired immune deficiency syndrome (AIDS). Because of preliminary data suggesting a possible role as an antiretroviral agent, dose-related toxicities of the drug were explored in the mid-1980s. At high doses in patients with AIDS-related complex, a polyarthralgia syndrome developed, accompanied in some parts by uveitis. While having no useful activity in vivo against HIV-1, rifabutin appeared to prevent or delay the onset of clinically disseminated MAC infections in AIDS patients. These preliminary studies led to two identical prospective, placebo-controlled trials of rifabutin for the prevention of disseminated MAC infection, in which the principal endpoint was the reduction of MAC bacteraemia. Over 1100 subjects who had prior AIDS-defining opportunistic infections and ≤ 200 CD4 cells·mm-3 were randomized. Rifabutin use was associated with significant reduction in the frequency of MAC bacteraemia (60%), with concomitant reductions in symptoms related to MAC. Drug-related toxicity was minimal. These studies established the principal of MAC prophylaxis, as well as the safety and efficacy of rifabutin for the prevention of MAC infections in AIDS.

AB - Rifabutin (formerly ansamycin), a semisynthetic derivative of rifamycin-S, has been in clinical use since 1982, initially as part of clinical efforts to treat disseminated infections with Mycobacterium avium complex (MAC) in the acquired immune deficiency syndrome (AIDS). Because of preliminary data suggesting a possible role as an antiretroviral agent, dose-related toxicities of the drug were explored in the mid-1980s. At high doses in patients with AIDS-related complex, a polyarthralgia syndrome developed, accompanied in some parts by uveitis. While having no useful activity in vivo against HIV-1, rifabutin appeared to prevent or delay the onset of clinically disseminated MAC infections in AIDS patients. These preliminary studies led to two identical prospective, placebo-controlled trials of rifabutin for the prevention of disseminated MAC infection, in which the principal endpoint was the reduction of MAC bacteraemia. Over 1100 subjects who had prior AIDS-defining opportunistic infections and ≤ 200 CD4 cells·mm-3 were randomized. Rifabutin use was associated with significant reduction in the frequency of MAC bacteraemia (60%), with concomitant reductions in symptoms related to MAC. Drug-related toxicity was minimal. These studies established the principal of MAC prophylaxis, as well as the safety and efficacy of rifabutin for the prevention of MAC infections in AIDS.

KW - Acquired immunodeficiency syndrome

KW - Human immunodeficiency virus

KW - Mycobacterial prophylaxis

KW - Mycobacterium avium

KW - Rifabutin

UR - http://www.scopus.com/inward/record.url?scp=0028901334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028901334&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028901334

VL - 5

SP - 98

EP - 101

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 25

ER -